Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXG9ES)

Drug Name
RXI-109 Drug Info
Synonyms A45sd-RxNA
Indication
Disease Entry ICD 11 Status REF
Fibrosis GA14-GC01 Phase 2 [1]
Hypertrophic scars EE60 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMXG9ES

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting CCN2 messenger RNA (CCN2 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-06473871 DM9S3P7 Hypertrophic scars EE60 Phase 2 [4]
OLX10010 DMXL7HO Hypertrophic scars EE60 Phase 2 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CCN2 messenger RNA (CCN2 mRNA) TTIL516 CCN2_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT02246465) A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446.
4 A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861.
5 Clinical pipeline report, company report or official report of Olix Pharmaceuticals.